Favipiravir (Avigan) was approved in Japan in 2014 for treating viral strains unresponsive to current antivirals. It is a substituted pyrazine derivative that inhibits the replication of many RNA viruses. Now FDA completed Phase 3 clinical trial studying safety and efficacy of it for the treatment of uncomplicated influenza. And Favipiravir seemed to be effective in treating COVID-19. We have created a set of Building Blocks, which are similar to this molecule, to generate new ideas for your projects: